Tract Closure in PCNL
NCT: NCT07668817 · RECRUITING
Brief Summary
This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.
Frequently Asked Questions
What is Tract Closure in PCNL?
Tract Closure in PCNL is a clinical trial registered under NCT07668817. Current status: RECRUITING.
What is the status of NCT07668817?
The current status of NCT07668817 (Tract Closure in PCNL) is: RECRUITING.
When did Tract Closure in PCNL start?
Tract Closure in PCNL started on 2026-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.